{"id":50984,"date":"2022-11-17T12:04:03","date_gmt":"2022-11-17T11:04:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-worldwide-hemophilia-treatment-industry-is-projected-to-reach-26-9-billion-by-2031-researchandmarkets-com\/"},"modified":"2022-11-17T12:04:03","modified_gmt":"2022-11-17T11:04:03","slug":"the-worldwide-hemophilia-treatment-industry-is-projected-to-reach-26-9-billion-by-2031-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-worldwide-hemophilia-treatment-industry-is-projected-to-reach-26-9-billion-by-2031-researchandmarkets-com\/","title":{"rendered":"The Worldwide Hemophilia Treatment Industry is Projected to Reach $26.9 Billion by 2031 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Hemophilia Treatment Market By Type, By Drug Therapy: Global Opportunity Analysis and Industry Forecast, 2021-2031”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global hemophilia treatment market was valued at $12,764.8 million in 2021, and is projected to reach $26,905.2 million by 2031, registering a CAGR of 7.5% from 2022 to 2031.\n<\/p>\n

\nHemophilia is usually an inherited bleeding disorder, in which the blood does not clot properly. This can lead to spontaneous bleeding, followed by injuries or surgery. Blood contains many proteins called clotting factors, which can help stop the bleeding.\n<\/p>\n

\nPeople with hemophilia have low levels of factor VIII or factor IX. The severity of hemophilia that a person has is determined by the amount of factor in the blood. Hemophilia is caused by a mutation or change in one of the genes that provides instructions for making the clotting factor proteins needed to form a blood clot.\n<\/p>\n

\nThere are two major types of hemophilia, namely hemophilia A and hemophilia B. The treatment of hemophilia involves replacement of missing blood clotting factor so that the blood can clot properly. This is done by infusion, in which the commercially prepared factor concentrates are administered through a vein. People with hemophilia can learn how to perform these infusions themselves so that they can stop bleeding episodes and, by performing the infusions on a regular basis can even prevent most bleeding episodes.\n<\/p>\n

\nThe major factors that drive the growth of the global hemophilia treatment market include: increase in the prevalence of hemophilia, technological advancements in the treatment of hemophilia, and favorable government initiatives for hemophilia management. In addition, increase in target population, increased diagnosis rate, and rise in the use of prophylactic treatment for hemophilia also propel the market growth.\n<\/p>\n

\nHowever, high cost of hemophilia treatment, lack of medicines of hemophilia, and serious adverse effects associated with plasma derived products are expected to restrict the market growth. Conversely, the rise in the awareness about hemophilia in developing countries provides lucrative opportunities for the growth of the market.\n<\/p>\n

\nKey Benefits<\/strong>\n<\/p>\n